<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196975</url>
  </required_header>
  <id_info>
    <org_study_id>112963</org_study_id>
    <nct_id>NCT01196975</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults</brief_title>
  <official_title>Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study is designed to test the immunogenicity and safety of an investigational influenza
      vaccine, in adults compared to two other influenza vaccines.

      This study will also evaluate the lot-to-lot consistency of three vaccine lots.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</measure>
    <time_frame>At Day 0 (D0) and at Day 21 (D21) post vaccination.</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Results for Day 21 for the subjects in the GSK2282512A Group are the results specific to this primary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</measure>
    <time_frame>At Day 0 (D0) and at Day 21 (D21) post vaccination.</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 flu strains. Subjects were assessed according to 2 age categories, 18-64Y and ≥ 65Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</measure>
    <time_frame>At Day 0 (D0), and at Day 21 (D21) and Day 180 (D180) post vaccination.</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 flu strains. Subjects were assessed according to 2 age categories, 18-60Y and ≥ 61Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Medically-attended Adverse Events (MAEs)</measure>
    <time_frame>From the beginning of the study until study end (from Day 0 to Day 180)</time_frame>
    <description>Medically-attended adverse events (MAEs) were non-serious and serious events leading to an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. If a medically-attended adverse event was leading to hospitalization (or met any other serious adverse event [SAE] criterion), it was reported as SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Related Medically-attended Adverse Events (MAEs)</measure>
    <time_frame>From the beginning of the study until study end (from Day 0 to Day 180) .</time_frame>
    <description>Medically-attended adverse events (MAEs) were non-serious and serious events leading to an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. If a medically-attended adverse event was leading to hospitalization (or met any other serious adverse event [SAE] criterion), it was reported as SAE. Related MAE = MAE assessed by the investigator to be causally related to vaccination. Relationship to vaccination was not computed for MAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs)</measure>
    <time_frame>From the beginning of the study until study end (from Day 0 to Day 180) .</time_frame>
    <description>Potential immune-mediated diseases (pIMDs) are a subset of adverse events that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related pIMD = pIMD assessed by the investigator to be causally related to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Related Serious Adverse Events (SAEs)</measure>
    <time_frame>From the beginning of the study until study end (from Day 0 to Day 180)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</measure>
    <time_frame>At Day 0 (D0), and at Day 21 (D21) and Day 180 (D180) post vaccination.</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 flu strains. Subjects were assessed according to 2 age categories, 18-64Y and ≥ 65Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease</measure>
    <time_frame>At Day 0 (D0) and at Day 21 (D21) after vaccination.</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition titer ≥ 1:40. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata</measure>
    <time_frame>At Day 0 (D0) and at Day 21 (D21) after vaccination.</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition titer ≥ 1:40. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-60Y and ≥ 61Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata</measure>
    <time_frame>At Day 0 (D0) and at Day 21 (D21) after vaccination</time_frame>
    <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition titer ≥ 1:40. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-64Y and ≥ 65Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against 4 Strains of Influenza by Age Strata</measure>
    <time_frame>At Day 21 (D21) after vaccination.</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-64Y and ≥ 65Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</measure>
    <time_frame>At Day 21 (D21) after vaccination</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0 (i.e. the geometric mean of the within-subject ratios of the Day 21 reciprocal HI titer to the Day 0 reciprocal HI titer). The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-64Y and ≥ 65Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</measure>
    <time_frame>At Day 0 (D0) and at Day 21 (D21) post vaccination.</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 flu strains. Subjects were assessed according to 2 age categories, 18-60Y and ≥ 61Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</measure>
    <time_frame>At Day 0 (D0), and at Day 21 (D21) and Day 180 (D180) post vaccination.</time_frame>
    <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 flu strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against 4 Strains of Influenza</measure>
    <time_frame>At Day 21 (D21) after vaccination.</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against 4 Strains of Influenza by Age Strata</measure>
    <time_frame>At Day 21 (D21) after vaccination.</time_frame>
    <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-60Y and ≥ 61Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</measure>
    <time_frame>At Day 21 (D21) post vaccination.</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0 (i.e. the geometric mean of the within-subject ratios of the Day 21 reciprocal HI titer to the Day 0 reciprocal HI titer). The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-60Y and ≥ 61Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</measure>
    <time_frame>At Day 21 (D21) post vaccination.</time_frame>
    <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0 (i.e. the geometric mean of the within-subject ratios of the Day 21 reciprocal HI titer to the Day 0 reciprocal HI titer). The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>Within the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
    <description>Assessed solicited local symptoms were pain, redness and swelling at the injection site. Grade 3 pain = significant pain at rest/pain that prevented normal everyday activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>Within the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
    <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (Gastr. Symptoms), headache, muscle ache, shivering, temperature - oral temperature equal to or above (≥) 38.0 degrees Celsius (°C) - and joint pain at location other than the injection site (Joint Pain). Grade 3 temperature = temperature ≥ 39.0 °C. Grade 3 symptom = symptom that prevented normal everyday activity. Related symptom = symptom assessed by the investigator as causally related to study vaccination. Joint pain data were collected for subjects in Canada and Mexico only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Within the 21-day (Days 0-20) follow-up period after vaccination</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal everyday activity Related: unsolicited AE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Solicited Local Symptoms After Vaccination.</measure>
    <time_frame>Within the 7-day follow-up period after vaccination (Days 0-6)</time_frame>
    <description>Solicited local symptoms were pain, redness and swelling at the injection site. Analyses of duration for solicited local symptoms were not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Solicited General Symptoms After Vaccination</measure>
    <time_frame>Within the 7-day follow-up period after vaccination (Days 0-6)</time_frame>
    <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (Gastr.), headache, muscle ache, shivering, temperature (defined as oral temperature equal to or above 38.0 degrees Celsius) and joint pain at location other than the injection site (Joint Pain). Joint pain data were collected for subjects in Canada and Mexico only. Analyses of duration for solicited general symptoms were not performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Unsolicited Adverse Events (AEs) After Vaccination</measure>
    <time_frame>Within the 21-day (Days 0-20) follow-up period post vaccination</time_frame>
    <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any: any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal everyday activity. Analyses of duration for unsolicited AEs were not performed.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1707</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>GSK2282512A 1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2282512A 2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK2282512A 3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Victoria Strain FluLaval Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Yamagata Strain FluLaval Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent seasonal influenza vaccine GSK2282512A</intervention_name>
    <description>Single intramuscular dose</description>
    <arm_group_label>GSK2282512A 3 Group</arm_group_label>
    <arm_group_label>GSK2282512A 1 Group</arm_group_label>
    <arm_group_label>GSK2282512A 2 Group</arm_group_label>
    <other_name>GSK2282512A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluLavalTM-VB</intervention_name>
    <description>Single intramuscular dose</description>
    <arm_group_label>Victoria Strain FluLaval Group</arm_group_label>
    <other_name>FluLavalTM containing the Victoria B flu strain</other_name>
    <other_name>FluLaval®-VB</other_name>
    <other_name>Victoria Strain FluLaval vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluLavalTM-YB</intervention_name>
    <description>Single intramuscular dose</description>
    <arm_group_label>Yamagata Strain FluLaval Group</arm_group_label>
    <other_name>FluLavalTM containing the Yamagata B flu strain</other_name>
    <other_name>FluLaval®-YB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol

          -  A male or female 18 years of age or older, in stable health, as established by medical
             history and physical examination before entering into the study.

          -  Written informed consent obtained from the subject.

          -  Access to a consistent means of telephone contact, which may be either in the home or
             at the workplace, land line, or mobile, but NOT a pay phone or other multiple-user
             device.

          -  Female subjects of non-childbearing potential may be enrolled in the study.

          -  Female subjects of childbearing potential may be enrolled in the study, if the
             subject:

          -  - has practiced adequate contraception for 30 days prior to vaccination, and

          -  - has a negative pregnancy test on the day of vaccination, and

          -  - has agreed to continue adequate contraception during the entire treatment period and
             for 2 months after completion of the vaccination series.

        Exclusion Criteria:

          -  Use of an investigational / non-registered product other than the study vaccines
             within 30 days before study vaccination or planned use during study period.

          -  Planned administration or administration of a licensed vaccine within 30 days before
             study vaccination.

          -  Prior receipt of 2010/2011 influenza vaccine.

          -  Receipt of any investigational or approved influenza vaccine within six months of the
             first study visit.

          -  Any known or suspected allergy to any constituent of influenza vaccines ; a history of
             anaphylactic-type reaction to constituent of vaccine; or a history of severe adverse
             reaction to a previous influenza vaccine.

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccines.

          -  History of Guillain-Barre syndrome within 6 weeks of receipt of prior inactivated
             influenza virus vaccine.

          -  Presence or evidence of substance abuse or of neurological or psychiatric diagnoses
             which, even if clinically stable, are deemed by the investigator to render the
             potential subject unable / unlikely to provide accurate safety reports.

          -  Acute, clinically significant pulmonary, cardiovascular, hepatic or renal functional
             abnormality, based on history and physical examination.

          -  Presence of significant uncontrolled chronic medical or neuropsychiatric illness,
             based on history and physical examination

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination.

          -  Any significant disorder of coagulation or treatment with Coumadin derivatives or
             heparin

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within 3
             months prior to the first vaccine/product dose.

          -  Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the first dose of study vaccine or planned administration during the study
             period.

          -  Pregnant or lactating female.

          -  Fever at the time of enrolment.

          -  Acute disease at the time of enrolment

          -  Any other condition which, in the opinion of the Investigator, prevents the subject
             from participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jefferson Hills</city>
        <state>Pennsylvania</state>
        <zip>15025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <zip>V3K 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 8P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durango</city>
        <zip>3400</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Estado de Mexico</city>
        <zip>55075</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <results_first_submitted>November 21, 2012</results_first_submitted>
  <results_first_submitted_qc>November 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 24, 2012</results_first_posted>
  <disposition_first_submitted>March 7, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>March 7, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 8, 2012</disposition_first_posted>
  <last_update_submitted>September 9, 2016</last_update_submitted>
  <last_update_submitted_qc>September 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>112963</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112963</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112963</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112963</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112963</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112963</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112963</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1703 of the 1707 subjects enrolled in the study were actually administered vaccination. The other 4 subjects were not vaccinated due to failing at meeting protocol specific criteria.</recruitment_details>
      <pre_assignment_details>For some outcome measures, the subjects receiving the GSK2282512A vaccine, from Lot 1, 2 or 3, were pooled into one larger pooled group, the GSK2282512A Group, and/or groups were stratified into the 4 age categories: 18 to 60 years (18-60Y), 61 years and older (≥61Y), 18 to 64 years (18-64Y), and 65 years and older (≥ 65Y).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK2282512A 1 Group</title>
          <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P2">
          <title>GSK2282512A 2 Group</title>
          <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P3">
          <title>GSK2282512A 3 Group</title>
          <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P4">
          <title>Victoria Strain FluLaval Group</title>
          <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="P5">
          <title>Yamagata Strain FluLaval Group</title>
          <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="423"/>
                <participants group_id="P2" count="424"/>
                <participants group_id="P3" count="425"/>
                <participants group_id="P4" count="213"/>
                <participants group_id="P5" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="408"/>
                <participants group_id="P2" count="415"/>
                <participants group_id="P3" count="420"/>
                <participants group_id="P4" count="207"/>
                <participants group_id="P5" count="205"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK2282512A 1 Group</title>
          <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm</description>
        </group>
        <group group_id="B2">
          <title>GSK2282512A 2 Group</title>
          <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B3">
          <title>GSK2282512A 3 Group</title>
          <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B4">
          <title>Victoria Strain FluLaval Group</title>
          <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B5">
          <title>Yamagata Strain FluLaval Group</title>
          <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="423"/>
            <count group_id="B2" value="424"/>
            <count group_id="B3" value="425"/>
            <count group_id="B4" value="213"/>
            <count group_id="B5" value="218"/>
            <count group_id="B6" value="1703"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" spread="19.49"/>
                    <measurement group_id="B2" value="50.4" spread="19.07"/>
                    <measurement group_id="B3" value="49.8" spread="20.10"/>
                    <measurement group_id="B4" value="50.8" spread="18.58"/>
                    <measurement group_id="B5" value="49.6" spread="19.34"/>
                    <measurement group_id="B6" value="50.1" spread="19.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="264"/>
                    <measurement group_id="B3" value="266"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="138"/>
                    <measurement group_id="B6" value="1044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="80"/>
                    <measurement group_id="B6" value="659"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</title>
        <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 flu strains. Subjects were assessed according to 2 age categories, 18-64Y and ≥ 65Y.</description>
        <time_frame>At Day 0 (D0) and at Day 21 (D21) post vaccination.</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 18-64Y Group</title>
            <description>Subjects aged between 18 and up to 64 years inclusive at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A ≥ 65Y Group</title>
            <description>Subjects aged 65 years or above at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Victoria Strain FluLaval 18-64Y Group</title>
            <description>Subjects aged between 18 and up to 64 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval ≥ 65Y Group</title>
            <description>Subjects aged 65 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval 18-64Y Group</title>
            <description>Subjects aged between 18 and up to 64 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Yamagata Strain FluLaval ≥ 65Y Group</title>
            <description>Subjects aged 65 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</title>
          <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 flu strains. Subjects were assessed according to 2 age categories, 18-64Y and ≥ 65Y.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="849"/>
                <count group_id="O2" value="397"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="144"/>
                <count group_id="O6" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, D0 (N=844;394;136;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="17.4" upper_limit="20.9"/>
                    <measurement group_id="O2" value="13.2" lower_limit="11.7" upper_limit="14.7"/>
                    <measurement group_id="O3" value="20.3" lower_limit="16.0" upper_limit="25.8"/>
                    <measurement group_id="O4" value="16.8" lower_limit="12.3" upper_limit="22.9"/>
                    <measurement group_id="O5" value="18.7" lower_limit="15.0" upper_limit="23.2"/>
                    <measurement group_id="O6" value="12.6" lower_limit="9.6" upper_limit="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, D21 (N=849;397;136;68;143;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289.4" lower_limit="267.9" upper_limit="312.7"/>
                    <measurement group_id="O2" value="97.4" lower_limit="85.9" upper_limit="110.5"/>
                    <measurement group_id="O3" value="236.9" lower_limit="199.7" upper_limit="281.1"/>
                    <measurement group_id="O4" value="97.1" lower_limit="70.3" upper_limit="134.1"/>
                    <measurement group_id="O5" value="198.5" lower_limit="161.7" upper_limit="243.7"/>
                    <measurement group_id="O6" value="80.8" lower_limit="55.1" upper_limit="118.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D0 (N=844;394;136;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="14.0" upper_limit="16.6"/>
                    <measurement group_id="O2" value="17.8" lower_limit="15.9" upper_limit="19.9"/>
                    <measurement group_id="O3" value="15.0" lower_limit="12.1" upper_limit="18.4"/>
                    <measurement group_id="O4" value="12.0" lower_limit="9.1" upper_limit="15.8"/>
                    <measurement group_id="O5" value="14.8" lower_limit="12.1" upper_limit="18.1"/>
                    <measurement group_id="O6" value="15.1" lower_limit="11.6" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D21 (N=849;396;136;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.1" lower_limit="125.9" upper_limit="147.2"/>
                    <measurement group_id="O2" value="105.1" lower_limit="93.4" upper_limit="118.3"/>
                    <measurement group_id="O3" value="176.3" lower_limit="144.3" upper_limit="215.4"/>
                    <measurement group_id="O4" value="103.2" lower_limit="75.1" upper_limit="141.8"/>
                    <measurement group_id="O5" value="173.6" lower_limit="142.5" upper_limit="211.6"/>
                    <measurement group_id="O6" value="90.1" lower_limit="63.8" upper_limit="127.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D0 (N=843;397;135;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7" lower_limit="19.9" upper_limit="23.7"/>
                    <measurement group_id="O2" value="47.9" lower_limit="42.8" upper_limit="53.5"/>
                    <measurement group_id="O3" value="23.8" lower_limit="19.1" upper_limit="29.6"/>
                    <measurement group_id="O4" value="44.7" lower_limit="34.1" upper_limit="58.6"/>
                    <measurement group_id="O5" value="22.8" lower_limit="18.7" upper_limit="27.8"/>
                    <measurement group_id="O6" value="37.6" lower_limit="28.8" upper_limit="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D21 (N=849;397;136;68;143;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199.3" lower_limit="185.9" upper_limit="213.6"/>
                    <measurement group_id="O2" value="139.0" lower_limit="126.2" upper_limit="153.1"/>
                    <measurement group_id="O3" value="157.2" lower_limit="131.5" upper_limit="187.9"/>
                    <measurement group_id="O4" value="101.6" lower_limit="81.8" upper_limit="126.1"/>
                    <measurement group_id="O5" value="75.1" lower_limit="61.2" upper_limit="92.2"/>
                    <measurement group_id="O6" value="65.4" lower_limit="51.3" upper_limit="83.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D0 (N=844;397;136;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.7" lower_limit="64.8" upper_limit="77.2"/>
                    <measurement group_id="O2" value="89.1" lower_limit="80.2" upper_limit="98.9"/>
                    <measurement group_id="O3" value="66.1" lower_limit="54.3" upper_limit="80.4"/>
                    <measurement group_id="O4" value="72.2" lower_limit="57.2" upper_limit="91.2"/>
                    <measurement group_id="O5" value="67.6" lower_limit="54.8" upper_limit="83.4"/>
                    <measurement group_id="O6" value="76.3" lower_limit="59.9" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D21 (N=849;397;136;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="475.3" lower_limit="444.2" upper_limit="508.5"/>
                    <measurement group_id="O2" value="276.1" lower_limit="252.8" upper_limit="301.5"/>
                    <measurement group_id="O3" value="204.9" lower_limit="171.3" upper_limit="245.0"/>
                    <measurement group_id="O4" value="131.8" lower_limit="107.1" upper_limit="162.3"/>
                    <measurement group_id="O5" value="406.1" lower_limit="347.3" upper_limit="474.9"/>
                    <measurement group_id="O6" value="167.7" lower_limit="132.0" upper_limit="212.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</title>
        <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 flu strains. Subjects were assessed according to 2 age categories, 18-60Y and ≥ 61Y.</description>
        <time_frame>At Day 0 (D0), and at Day 21 (D21) and Day 180 (D180) post vaccination.</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all vaccinated subjects who had not received a vaccine forbidden in the protocol with available assay results for assessed antibodies in Day 180 blood samples.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 18-60Y Group</title>
            <description>Subjects aged between 18 and up to 60 years inclusive at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A ≥ 61Y Group</title>
            <description>Subjects aged 61 years or above at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Victoria Strain FluLaval 18-60Y Group</title>
            <description>Subjects aged between 18 and up to 60 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval ≥ 61Y Group</title>
            <description>Subjects aged 61 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval 18-60Y Group</title>
            <description>Subjects aged between 18 and up to 60 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Yamagata Strain FluLaval ≥ 61Y Group</title>
            <description>Subjects aged 61 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</title>
          <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 flu strains. Subjects were assessed according to 2 age categories, 18-60Y and ≥ 61Y.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for persistence, which included all vaccinated subjects who had not received a vaccine forbidden in the protocol with available assay results for assessed antibodies in Day 180 blood samples.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="135"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, D0 (N=122;135;17;20;22;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" lower_limit="17.9" upper_limit="29.8"/>
                    <measurement group_id="O2" value="12.0" lower_limit="9.9" upper_limit="14.5"/>
                    <measurement group_id="O3" value="22.6" lower_limit="11.6" upper_limit="44.0"/>
                    <measurement group_id="O4" value="18.7" lower_limit="8.7" upper_limit="39.9"/>
                    <measurement group_id="O5" value="17.9" lower_limit="10.0" upper_limit="32.1"/>
                    <measurement group_id="O6" value="10.2" lower_limit="6.1" upper_limit="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, D21 (N=122;135;17;20;22;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.4" lower_limit="245.8" upper_limit="372.0"/>
                    <measurement group_id="O2" value="105.0" lower_limit="83.6" upper_limit="131.9"/>
                    <measurement group_id="O3" value="369.1" lower_limit="216.2" upper_limit="630.0"/>
                    <measurement group_id="O4" value="132.2" lower_limit="64.5" upper_limit="270.7"/>
                    <measurement group_id="O5" value="187.4" lower_limit="110.4" upper_limit="318.2"/>
                    <measurement group_id="O6" value="81.4" lower_limit="34.2" upper_limit="194.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, D180 (N=122;135;17;20;22;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="80.3" upper_limit="119.3"/>
                    <measurement group_id="O2" value="29.1" lower_limit="23.4" upper_limit="36.2"/>
                    <measurement group_id="O3" value="104.2" lower_limit="57.0" upper_limit="190.5"/>
                    <measurement group_id="O4" value="55.6" lower_limit="29.3" upper_limit="105.6"/>
                    <measurement group_id="O5" value="57.5" lower_limit="33.2" upper_limit="99.4"/>
                    <measurement group_id="O6" value="34.8" lower_limit="16.2" upper_limit="74.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D0 (N=122;135;17;20;22;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="12.3" upper_limit="19.4"/>
                    <measurement group_id="O2" value="17.9" lower_limit="14.7" upper_limit="21.8"/>
                    <measurement group_id="O3" value="12.0" lower_limit="7.3" upper_limit="19.7"/>
                    <measurement group_id="O4" value="16.8" lower_limit="9.1" upper_limit="30.9"/>
                    <measurement group_id="O5" value="12.7" lower_limit="7.7" upper_limit="20.7"/>
                    <measurement group_id="O6" value="17.1" lower_limit="9.9" upper_limit="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D21 (N=122;134;17;20;22;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.2" lower_limit="100.4" upper_limit="151.2"/>
                    <measurement group_id="O2" value="119.8" lower_limit="97.6" upper_limit="147.0"/>
                    <measurement group_id="O3" value="163.3" lower_limit="103.0" upper_limit="258.8"/>
                    <measurement group_id="O4" value="168.4" lower_limit="82.1" upper_limit="345.6"/>
                    <measurement group_id="O5" value="175.9" lower_limit="110.7" upper_limit="279.3"/>
                    <measurement group_id="O6" value="157.2" lower_limit="92.3" upper_limit="267.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D180 (N=122;135;17;20;22;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9" lower_limit="33.5" upper_limit="49.9"/>
                    <measurement group_id="O2" value="43.3" lower_limit="36.7" upper_limit="51.1"/>
                    <measurement group_id="O3" value="46.1" lower_limit="31.8" upper_limit="67.0"/>
                    <measurement group_id="O4" value="46.7" lower_limit="27.6" upper_limit="79.0"/>
                    <measurement group_id="O5" value="63.0" lower_limit="39.5" upper_limit="100.8"/>
                    <measurement group_id="O6" value="60.6" lower_limit="35.1" upper_limit="104.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D0 (N=122;135;17;20;22;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.9" lower_limit="18.3" upper_limit="28.6"/>
                    <measurement group_id="O2" value="41.1" lower_limit="33.9" upper_limit="49.8"/>
                    <measurement group_id="O3" value="30.7" lower_limit="16.1" upper_limit="58.6"/>
                    <measurement group_id="O4" value="42.9" lower_limit="25.4" upper_limit="72.3"/>
                    <measurement group_id="O5" value="17.9" lower_limit="11.7" upper_limit="27.3"/>
                    <measurement group_id="O6" value="32.5" lower_limit="18.0" upper_limit="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D21 (N=122;135;17;20;22;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193.0" lower_limit="161.0" upper_limit="231.4"/>
                    <measurement group_id="O2" value="167.2" lower_limit="141.6" upper_limit="197.3"/>
                    <measurement group_id="O3" value="180.9" lower_limit="120.9" upper_limit="270.7"/>
                    <measurement group_id="O4" value="109.3" lower_limit="77.7" upper_limit="153.6"/>
                    <measurement group_id="O5" value="53.9" lower_limit="31.0" upper_limit="93.6"/>
                    <measurement group_id="O6" value="74.7" lower_limit="44.7" upper_limit="124.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D180 (N=122;135;17;20;22;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.8" lower_limit="94.1" upper_limit="135.3"/>
                    <measurement group_id="O2" value="127.0" lower_limit="109.1" upper_limit="147.8"/>
                    <measurement group_id="O3" value="130.5" lower_limit="91.8" upper_limit="185.4"/>
                    <measurement group_id="O4" value="102.0" lower_limit="78.8" upper_limit="132.0"/>
                    <measurement group_id="O5" value="59.3" lower_limit="36.9" upper_limit="95.4"/>
                    <measurement group_id="O6" value="79.9" lower_limit="49.8" upper_limit="128.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D0 (N=122;135;17;20;22;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4" lower_limit="59.3" upper_limit="95.8"/>
                    <measurement group_id="O2" value="79.2" lower_limit="65.5" upper_limit="95.7"/>
                    <measurement group_id="O3" value="92.3" lower_limit="54.5" upper_limit="156.4"/>
                    <measurement group_id="O4" value="93.5" lower_limit="54.0" upper_limit="161.7"/>
                    <measurement group_id="O5" value="60.3" lower_limit="38.7" upper_limit="93.9"/>
                    <measurement group_id="O6" value="78.6" lower_limit="41.6" upper_limit="148.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D21 (N=122;135;17;20;22;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="485.8" lower_limit="407.3" upper_limit="579.5"/>
                    <measurement group_id="O2" value="334.3" lower_limit="288.9" upper_limit="386.8"/>
                    <measurement group_id="O3" value="204.4" lower_limit="134.8" upper_limit="310.0"/>
                    <measurement group_id="O4" value="187.0" lower_limit="138.5" upper_limit="252.3"/>
                    <measurement group_id="O5" value="405.3" lower_limit="273.8" upper_limit="600.0"/>
                    <measurement group_id="O6" value="180.6" lower_limit="101.4" upper_limit="321.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D180 (N=122;135;17;20;22;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="311.9" lower_limit="261.7" upper_limit="371.7"/>
                    <measurement group_id="O2" value="209.5" lower_limit="183.0" upper_limit="239.8"/>
                    <measurement group_id="O3" value="177.3" lower_limit="120.5" upper_limit="260.9"/>
                    <measurement group_id="O4" value="160.1" lower_limit="108.8" upper_limit="235.6"/>
                    <measurement group_id="O5" value="320.1" lower_limit="207.8" upper_limit="492.9"/>
                    <measurement group_id="O6" value="174.3" lower_limit="104.3" upper_limit="291.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Medically-attended Adverse Events (MAEs)</title>
        <description>Medically-attended adverse events (MAEs) were non-serious and serious events leading to an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. If a medically-attended adverse event was leading to hospitalization (or met any other serious adverse event [SAE] criterion), it was reported as SAE.</description>
        <time_frame>From the beginning of the study until study end (from Day 0 to Day 180)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2282512A 3 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Medically-attended Adverse Events (MAEs)</title>
          <description>Medically-attended adverse events (MAEs) were non-serious and serious events leading to an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. If a medically-attended adverse event was leading to hospitalization (or met any other serious adverse event [SAE] criterion), it was reported as SAE.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, on subjects with available results.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="424"/>
                <count group_id="O3" value="425"/>
                <count group_id="O4" value="213"/>
                <count group_id="O5" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Related Medically-attended Adverse Events (MAEs)</title>
        <description>Medically-attended adverse events (MAEs) were non-serious and serious events leading to an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. If a medically-attended adverse event was leading to hospitalization (or met any other serious adverse event [SAE] criterion), it was reported as SAE. Related MAE = MAE assessed by the investigator to be causally related to vaccination. Relationship to vaccination was not computed for MAEs.</description>
        <time_frame>From the beginning of the study until study end (from Day 0 to Day 180) .</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2282512A 3 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Related Medically-attended Adverse Events (MAEs)</title>
          <description>Medically-attended adverse events (MAEs) were non-serious and serious events leading to an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits. If a medically-attended adverse event was leading to hospitalization (or met any other serious adverse event [SAE] criterion), it was reported as SAE. Related MAE = MAE assessed by the investigator to be causally related to vaccination. Relationship to vaccination was not computed for MAEs.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, on subjects with available results.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs)</title>
        <description>Potential immune-mediated diseases (pIMDs) are a subset of adverse events that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related pIMD = pIMD assessed by the investigator to be causally related to vaccination.</description>
        <time_frame>From the beginning of the study until study end (from Day 0 to Day 180) .</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, on subjects with available results.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2282512A 3 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Related Potential Immune-mediated Diseases (pIMDs)</title>
          <description>Potential immune-mediated diseases (pIMDs) are a subset of adverse events that include both clearly autoimmune diseases and also other inflammatory and/or neurologic disorders which may or may not have an autoimmune etiology. Related pIMD = pIMD assessed by the investigator to be causally related to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, on subjects with available results.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="424"/>
                <count group_id="O3" value="425"/>
                <count group_id="O4" value="213"/>
                <count group_id="O5" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subject(s) with Any pIMD(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject(s) with Related pIMD(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
        <time_frame>From the beginning of the study until study end (from Day 0 to Day 180)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2282512A 3 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Related Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="424"/>
                <count group_id="O3" value="425"/>
                <count group_id="O4" value="213"/>
                <count group_id="O5" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subject(s) with Any SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject(s) with Related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</title>
        <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 flu strains. Subjects were assessed according to 2 age categories, 18-64Y and ≥ 65Y.</description>
        <time_frame>At Day 0 (D0), and at Day 21 (D21) and Day 180 (D180) post vaccination.</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for persistence, which included all vaccinated subjects who had not received a vaccine forbidden in the protocol, and with available assay results at Day 180 for assessed antibodies.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 18-64Y Group</title>
            <description>Subjects aged between 18 and up to 64 years inclusive at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A ≥ 65Y Group</title>
            <description>Subjects aged 65 years or above at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Victoria Strain FluLaval 18-64Y Group</title>
            <description>Subjects aged between 18 and up to 64 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval ≥ 65Y Group</title>
            <description>Subjects aged 65 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval 18-64Y Group</title>
            <description>Subjects aged between 18 and up to 64 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Yamagata Strain FluLaval ≥ 65Y Group</title>
            <description>Subjects aged 65 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</title>
          <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 flu strains. Subjects were assessed according to 2 age categories, 18-64Y and ≥ 65Y.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for persistence, which included all vaccinated subjects who had not received a vaccine forbidden in the protocol, and with available assay results at Day 180 for assessed antibodies.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="126"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, D0 (N=131;126;18;19;23;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="17.8" upper_limit="29.0"/>
                    <measurement group_id="O2" value="11.6" lower_limit="9.6" upper_limit="14.2"/>
                    <measurement group_id="O3" value="23.3" lower_limit="12.4" upper_limit="43.7"/>
                    <measurement group_id="O4" value="17.9" lower_limit="8.1" upper_limit="39.8"/>
                    <measurement group_id="O5" value="18.0" lower_limit="10.3" upper_limit="31.4"/>
                    <measurement group_id="O6" value="9.8" lower_limit="5.7" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, D21 (N=131;126;18;19;23;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293.3" lower_limit="240.7" upper_limit="357.3"/>
                    <measurement group_id="O2" value="100.5" lower_limit="79.1" upper_limit="127.7"/>
                    <measurement group_id="O3" value="339.0" lower_limit="199.0" upper_limit="577.6"/>
                    <measurement group_id="O4" value="135.7" lower_limit="63.7" upper_limit="289.2"/>
                    <measurement group_id="O5" value="180.6" lower_limit="108.4" upper_limit="300.8"/>
                    <measurement group_id="O6" value="81.5" lower_limit="32.5" upper_limit="204.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, D180 (N=131;126;18;19;23;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.5" lower_limit="79.1" upper_limit="115.3"/>
                    <measurement group_id="O2" value="27.4" lower_limit="21.8" upper_limit="34.4"/>
                    <measurement group_id="O3" value="98.8" lower_limit="55.5" upper_limit="176.0"/>
                    <measurement group_id="O4" value="56.6" lower_limit="28.7" upper_limit="111.4"/>
                    <measurement group_id="O5" value="56.6" lower_limit="33.5" upper_limit="95.4"/>
                    <measurement group_id="O6" value="34.5" lower_limit="15.4" upper_limit="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D0 (N=131;126;18;19;23;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" lower_limit="12.2" upper_limit="19.1"/>
                    <measurement group_id="O2" value="18.4" lower_limit="15.1" upper_limit="22.3"/>
                    <measurement group_id="O3" value="13.3" lower_limit="8.0" upper_limit="22.4"/>
                    <measurement group_id="O4" value="15.5" lower_limit="8.3" upper_limit="28.8"/>
                    <measurement group_id="O5" value="12.2" lower_limit="7.5" upper_limit="19.6"/>
                    <measurement group_id="O6" value="18.2" lower_limit="10.4" upper_limit="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D21 (N=131;125;18;19;23;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.0" lower_limit="93.2" upper_limit="141.9"/>
                    <measurement group_id="O2" value="128.6" lower_limit="105.4" upper_limit="156.8"/>
                    <measurement group_id="O3" value="163.1" lower_limit="105.8" upper_limit="251.3"/>
                    <measurement group_id="O4" value="168.9" lower_limit="79.0" upper_limit="361.3"/>
                    <measurement group_id="O5" value="175.1" lower_limit="112.7" upper_limit="272.2"/>
                    <measurement group_id="O6" value="157.1" lower_limit="89.4" upper_limit="276.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D180 (N=131;126;18;19;23;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" lower_limit="34.0" upper_limit="50.0"/>
                    <measurement group_id="O2" value="43.1" lower_limit="36.3" upper_limit="51.0"/>
                    <measurement group_id="O3" value="49.4" lower_limit="33.8" upper_limit="72.2"/>
                    <measurement group_id="O4" value="43.8" lower_limit="25.6" upper_limit="74.9"/>
                    <measurement group_id="O5" value="61.9" lower_limit="39.5" upper_limit="96.9"/>
                    <measurement group_id="O6" value="61.9" lower_limit="34.8" upper_limit="110.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D0 (N=131;126;18;19;23;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1" lower_limit="18.6" upper_limit="28.6"/>
                    <measurement group_id="O2" value="42.5" lower_limit="34.8" upper_limit="51.8"/>
                    <measurement group_id="O3" value="29.9" lower_limit="16.3" upper_limit="55.1"/>
                    <measurement group_id="O4" value="44.6" lower_limit="25.9" upper_limit="77.0"/>
                    <measurement group_id="O5" value="19.7" lower_limit="12.6" upper_limit="30.8"/>
                    <measurement group_id="O6" value="29.9" lower_limit="16.5" upper_limit="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D21 (N=131;126;18;19;23;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183.6" lower_limit="154.3" upper_limit="218.6"/>
                    <measurement group_id="O2" value="174.3" lower_limit="146.6" upper_limit="207.1"/>
                    <measurement group_id="O3" value="166.4" lower_limit="109.6" upper_limit="252.5"/>
                    <measurement group_id="O4" value="115.2" lower_limit="81.9" upper_limit="162.0"/>
                    <measurement group_id="O5" value="56.5" lower_limit="33.1" upper_limit="96.5"/>
                    <measurement group_id="O6" value="71.8" lower_limit="41.9" upper_limit="122.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D180 (N=131;126;18;19;23;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.1" lower_limit="93.6" upper_limit="131.8"/>
                    <measurement group_id="O2" value="130.2" lower_limit="111.0" upper_limit="152.7"/>
                    <measurement group_id="O3" value="124.6" lower_limit="88.4" upper_limit="175.7"/>
                    <measurement group_id="O4" value="105.2" lower_limit="80.8" upper_limit="137.0"/>
                    <measurement group_id="O5" value="63.8" lower_limit="39.6" upper_limit="102.9"/>
                    <measurement group_id="O6" value="74.3" lower_limit="46.2" upper_limit="119.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D0 (N=131;126;18;19;23;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" lower_limit="62.4" upper_limit="98.8"/>
                    <measurement group_id="O2" value="76.1" lower_limit="62.6" upper_limit="92.6"/>
                    <measurement group_id="O3" value="98.9" lower_limit="59.1" upper_limit="165.6"/>
                    <measurement group_id="O4" value="87.6" lower_limit="50.0" upper_limit="153.7"/>
                    <measurement group_id="O5" value="64.8" lower_limit="41.4" upper_limit="101.5"/>
                    <measurement group_id="O6" value="73.0" lower_limit="38.0" upper_limit="140.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D21 (N=131;126;18;19;23;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="473.4" lower_limit="399.7" upper_limit="560.6"/>
                    <measurement group_id="O2" value="334.4" lower_limit="287.4" upper_limit="389.1"/>
                    <measurement group_id="O3" value="209.5" lower_limit="141.3" upper_limit="310.8"/>
                    <measurement group_id="O4" value="181.7" lower_limit="133.2" upper_limit="248.0"/>
                    <measurement group_id="O5" value="401.2" lower_limit="275.9" upper_limit="583.3"/>
                    <measurement group_id="O6" value="175.3" lower_limit="95.5" upper_limit="321.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D180 (N=131;126;18;19;23;19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314.1" lower_limit="266.4" upper_limit="370.4"/>
                    <measurement group_id="O2" value="202.1" lower_limit="175.6" upper_limit="232.7"/>
                    <measurement group_id="O3" value="190.4" lower_limit="128.6" upper_limit="281.9"/>
                    <measurement group_id="O4" value="148.8" lower_limit="102.3" upper_limit="216.6"/>
                    <measurement group_id="O5" value="329.9" lower_limit="217.6" upper_limit="500.1"/>
                    <measurement group_id="O6" value="162.8" lower_limit="96.6" upper_limit="274.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease</title>
        <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition titer ≥ 1:40. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains</description>
        <time_frame>At Day 0 (D0) and at Day 21 (D21) after vaccination.</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease</title>
          <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition titer ≥ 1:40. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1246"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, D0 (N=1238;204;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, D21 (N=1246;204;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1168"/>
                    <measurement group_id="O2" value="189"/>
                    <measurement group_id="O3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D0 (N=1238;204;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="385"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D21 (N=1245;204;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1130"/>
                    <measurement group_id="O2" value="188"/>
                    <measurement group_id="O3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D0 (N=1240;203;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="635"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D21 (N=1246;204;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1201"/>
                    <measurement group_id="O2" value="193"/>
                    <measurement group_id="O3" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D0 (N=1241;204;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="997"/>
                    <measurement group_id="O2" value="162"/>
                    <measurement group_id="O3" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D21 (N=1246;204;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1244"/>
                    <measurement group_id="O2" value="200"/>
                    <measurement group_id="O3" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata</title>
        <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition titer ≥ 1:40. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-60Y and ≥ 61Y.</description>
        <time_frame>At Day 0 (D0) and at Day 21 (D21) after vaccination.</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 18-60Y Group</title>
            <description>Subjects aged between 18 and up to 60 years inclusive at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A ≥ 61Y Group</title>
            <description>Subjects aged 61 years or above at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Victoria Strain FluLaval 18-60Y Group</title>
            <description>Subjects aged between 18 and up to 60 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval ≥ 61Y Group</title>
            <description>Subjects aged 61 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval 18-60Y Group</title>
            <description>Subjects aged between 18 and up to 60 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Yamagata Strain FluLaval ≥ 61Y Group</title>
            <description>Subjects aged 61 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata</title>
          <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition titer ≥ 1:40. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-60Y and ≥ 61Y.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="780"/>
                <count group_id="O2" value="466"/>
                <count group_id="O3" value="127"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, D0 (N=775;463;127;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="27"/>
                    <measurement group_id="O5" value="50"/>
                    <measurement group_id="O6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, D21 (N=780;466;127;77;135;75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="765"/>
                    <measurement group_id="O2" value="403"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="64"/>
                    <measurement group_id="O5" value="127"/>
                    <measurement group_id="O6" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D0 (N=775;463;127;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="156"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="40"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D21 (N=780;465;127;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="726"/>
                    <measurement group_id="O2" value="404"/>
                    <measurement group_id="O3" value="122"/>
                    <measurement group_id="O4" value="66"/>
                    <measurement group_id="O5" value="130"/>
                    <measurement group_id="O6" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D0 (N=774;466;126;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338"/>
                    <measurement group_id="O2" value="297"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="51"/>
                    <measurement group_id="O5" value="53"/>
                    <measurement group_id="O6" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D21 (N=780;466;127;77;135;75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="760"/>
                    <measurement group_id="O2" value="441"/>
                    <measurement group_id="O3" value="121"/>
                    <measurement group_id="O4" value="72"/>
                    <measurement group_id="O5" value="107"/>
                    <measurement group_id="O6" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D0 (N=775;466;127;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="591"/>
                    <measurement group_id="O2" value="406"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="63"/>
                    <measurement group_id="O5" value="105"/>
                    <measurement group_id="O6" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D21 (N=780;466;127;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="779"/>
                    <measurement group_id="O2" value="465"/>
                    <measurement group_id="O3" value="125"/>
                    <measurement group_id="O4" value="75"/>
                    <measurement group_id="O5" value="134"/>
                    <measurement group_id="O6" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata</title>
        <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition titer ≥ 1:40. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-64Y and ≥ 65Y.</description>
        <time_frame>At Day 0 (D0) and at Day 21 (D21) after vaccination</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 18-64Y Group</title>
            <description>Subjects aged between 18 and up to 64 years inclusive at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A ≥ 65Y Group</title>
            <description>Subjects aged 65 years or above at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Victoria Strain FluLaval 18-64Y Group</title>
            <description>Subjects aged between 18 and up to 64 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval ≥ 65Y Group</title>
            <description>Subjects aged 65 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval 18-64Y Group</title>
            <description>Subjects aged between 18 and up to 64 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Yamagata Strain FluLaval ≥ 65Y Group</title>
            <description>Subjects aged 65 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroprotected Subjects Against 4 Strains of Influenza Disease by Age Strata</title>
          <description>A seroprotected subject was defined as a vaccinated subject with serum Hemagglutination Inhibition titer ≥ 1:40. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-64Y and ≥ 65Y.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="849"/>
                <count group_id="O2" value="397"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="144"/>
                <count group_id="O6" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, D0 (N=844;394;136;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="51"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, D21 (N=849;397;136;68;143;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="830"/>
                    <measurement group_id="O2" value="338"/>
                    <measurement group_id="O3" value="134"/>
                    <measurement group_id="O4" value="55"/>
                    <measurement group_id="O5" value="132"/>
                    <measurement group_id="O6" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D0 (N=844;394;136;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251"/>
                    <measurement group_id="O2" value="134"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D21 (N=849;396;136;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="784"/>
                    <measurement group_id="O2" value="346"/>
                    <measurement group_id="O3" value="129"/>
                    <measurement group_id="O4" value="59"/>
                    <measurement group_id="O5" value="137"/>
                    <measurement group_id="O6" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D0 (N=843;397;135;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366"/>
                    <measurement group_id="O2" value="269"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="59"/>
                    <measurement group_id="O6" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D21 (N=849;397;136;68;143;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="826"/>
                    <measurement group_id="O2" value="375"/>
                    <measurement group_id="O3" value="130"/>
                    <measurement group_id="O4" value="63"/>
                    <measurement group_id="O5" value="114"/>
                    <measurement group_id="O6" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D0 (N=844;397;136;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="650"/>
                    <measurement group_id="O2" value="347"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="57"/>
                    <measurement group_id="O5" value="112"/>
                    <measurement group_id="O6" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D21 (N=849;397;136;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="848"/>
                    <measurement group_id="O2" value="396"/>
                    <measurement group_id="O3" value="134"/>
                    <measurement group_id="O4" value="66"/>
                    <measurement group_id="O5" value="143"/>
                    <measurement group_id="O6" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against 4 Strains of Influenza by Age Strata</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-64Y and ≥ 65Y.</description>
        <time_frame>At Day 21 (D21) after vaccination.</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 18-64Y Group</title>
            <description>Subjects aged between 18 and up to 64 years inclusive at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A ≥ 65Y Group</title>
            <description>Subjects aged 65 years or above at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Victoria Strain FluLaval 18-64Y Group</title>
            <description>Subjects aged between 18 and up to 64 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval ≥ 65Y Group</title>
            <description>Subjects aged 65 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval 18-64Y Group</title>
            <description>Subjects aged between 18 and up to 64 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Yamagata Strain FluLaval ≥ 65Y Group</title>
            <description>Subjects aged 65 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against 4 Strains of Influenza by Age Strata</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-64Y and ≥ 65Y.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="844"/>
                <count group_id="O2" value="397"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="144"/>
                <count group_id="O6" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, D21 (N=844;394;136;68;143;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="667"/>
                    <measurement group_id="O2" value="255"/>
                    <measurement group_id="O3" value="101"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="102"/>
                    <measurement group_id="O6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D21 (N=844;393;136;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="584"/>
                    <measurement group_id="O2" value="239"/>
                    <measurement group_id="O3" value="104"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="109"/>
                    <measurement group_id="O6" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D21 (N=843;397;135;68;143;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="561"/>
                    <measurement group_id="O2" value="124"/>
                    <measurement group_id="O3" value="80"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="52"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D21 (N=844;397;136;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="533"/>
                    <measurement group_id="O2" value="147"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="90"/>
                    <measurement group_id="O6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</title>
        <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0 (i.e. the geometric mean of the within-subject ratios of the Day 21 reciprocal HI titer to the Day 0 reciprocal HI titer). The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-64Y and ≥ 65Y.</description>
        <time_frame>At Day 21 (D21) after vaccination</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 18-64Y Group</title>
            <description>Subjects aged between 18 and up to 64 years inclusive at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A ≥ 65Y Group</title>
            <description>Subjects aged 65 years or above at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Victoria Strain FluLaval 18-64Y Group</title>
            <description>Subjects aged between 18 and up to 64 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval ≥ 65Y Group</title>
            <description>Subjects aged 65 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval 18-64Y Group</title>
            <description>Subjects aged between 18 and up to 64 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Yamagata Strain FluLaval ≥ 65Y Group</title>
            <description>Subjects aged 65 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</title>
          <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0 (i.e. the geometric mean of the within-subject ratios of the Day 21 reciprocal HI titer to the Day 0 reciprocal HI titer). The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-64Y and ≥ 65Y.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="844"/>
                <count group_id="O2" value="397"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="144"/>
                <count group_id="O6" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCF – H1N1, D21 (N=844;394;136;68;143;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="13.7" upper_limit="16.9"/>
                    <measurement group_id="O2" value="7.4" lower_limit="6.4" upper_limit="8.4"/>
                    <measurement group_id="O3" value="11.7" lower_limit="9.0" upper_limit="15.1"/>
                    <measurement group_id="O4" value="5.8" lower_limit="4.0" upper_limit="8.3"/>
                    <measurement group_id="O5" value="10.5" lower_limit="8.2" upper_limit="13.4"/>
                    <measurement group_id="O6" value="6.4" lower_limit="4.3" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCF – H3N1, D21 (N=844;393;136;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="8.1" upper_limit="9.8"/>
                    <measurement group_id="O2" value="5.9" lower_limit="5.2" upper_limit="6.7"/>
                    <measurement group_id="O3" value="11.8" lower_limit="9.2" upper_limit="15.1"/>
                    <measurement group_id="O4" value="8.6" lower_limit="5.9" upper_limit="12.4"/>
                    <measurement group_id="O5" value="11.7" lower_limit="9.1" upper_limit="15.1"/>
                    <measurement group_id="O6" value="6.0" lower_limit="4.3" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCF – BRI, D21 (N=843;397;135;68;143;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" lower_limit="8.3" upper_limit="10.1"/>
                    <measurement group_id="O2" value="2.9" lower_limit="2.6" upper_limit="3.2"/>
                    <measurement group_id="O3" value="6.5" lower_limit="5.1" upper_limit="8.3"/>
                    <measurement group_id="O4" value="2.3" lower_limit="1.8" upper_limit="2.9"/>
                    <measurement group_id="O5" value="3.3" lower_limit="2.7" upper_limit="4.1"/>
                    <measurement group_id="O6" value="1.7" lower_limit="1.4" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCF – FLO, D21 (N=844;397;136;68;144;67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="6.1" upper_limit="7.4"/>
                    <measurement group_id="O2" value="3.1" lower_limit="2.8" upper_limit="3.4"/>
                    <measurement group_id="O3" value="3.1" lower_limit="2.6" upper_limit="3.7"/>
                    <measurement group_id="O4" value="1.8" lower_limit="1.5" upper_limit="2.3"/>
                    <measurement group_id="O5" value="6.0" lower_limit="4.8" upper_limit="7.5"/>
                    <measurement group_id="O6" value="2.2" lower_limit="1.8" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</title>
        <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Results for Day 21 for the subjects in the GSK2282512A Group are the results specific to this primary outcome measure.</description>
        <time_frame>At Day 0 (D0) and at Day 21 (D21) post vaccination.</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain FluLaval Group</title>
            <description>Yamagata Strain FluLaval Group - Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</title>
          <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Results for Day 21 for the subjects in the GSK2282512A Group are the results specific to this primary outcome measure.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1246"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, D0 (N=1238;204;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="15.7" upper_limit="18.2"/>
                    <measurement group_id="O2" value="19.1" lower_limit="15.8" upper_limit="23.1"/>
                    <measurement group_id="O3" value="16.5" lower_limit="13.9" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, D21 (N=1246;204;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204.6" lower_limit="190.4" upper_limit="219.9"/>
                    <measurement group_id="O2" value="176.0" lower_limit="149.1" upper_limit="207.7"/>
                    <measurement group_id="O3" value="149.0" lower_limit="122.9" upper_limit="180.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D0 (N=1238;204;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="15.0" upper_limit="17.1"/>
                    <measurement group_id="O2" value="13.9" lower_limit="11.8" upper_limit="16.4"/>
                    <measurement group_id="O3" value="14.9" lower_limit="12.7" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D21 (N=1245;204;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.4" lower_limit="117.4" upper_limit="133.9"/>
                    <measurement group_id="O2" value="147.5" lower_limit="124.1" upper_limit="175.2"/>
                    <measurement group_id="O3" value="141.0" lower_limit="118.1" upper_limit="168.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D0 (N=1240;203;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" lower_limit="26.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="29.4" lower_limit="24.7" upper_limit="35.0"/>
                    <measurement group_id="O3" value="26.7" lower_limit="22.8" upper_limit="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D21 (N=1246;204;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.7" lower_limit="167.8" upper_limit="188.1"/>
                    <measurement group_id="O2" value="135.9" lower_limit="118.1" upper_limit="156.5"/>
                    <measurement group_id="O3" value="71.9" lower_limit="61.3" upper_limit="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D0 (N=1241;204;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" lower_limit="71.1" upper_limit="81.5"/>
                    <measurement group_id="O2" value="68.1" lower_limit="58.5" upper_limit="79.2"/>
                    <measurement group_id="O3" value="70.3" lower_limit="59.8" upper_limit="82.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D21 (N=1246;204;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399.7" lower_limit="378.1" upper_limit="422.6"/>
                    <measurement group_id="O2" value="176.9" lower_limit="153.8" upper_limit="203.5"/>
                    <measurement group_id="O3" value="306.6" lower_limit="266.2" upper_limit="353.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</title>
        <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 flu strains. Subjects were assessed according to 2 age categories, 18-60Y and ≥ 61Y.</description>
        <time_frame>At Day 0 (D0) and at Day 21 (D21) post vaccination.</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 18-60Y Group</title>
            <description>Subjects aged between 18 and up to 60 years inclusive at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A ≥ 61Y Group</title>
            <description>Subjects aged 61 years or above at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Victoria Strain FluLaval 18-60Y Group</title>
            <description>Subjects aged between 18 and up to 60 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval ≥ 61Y Group</title>
            <description>Subjects aged 61 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval 18-60Y Group</title>
            <description>Subjects aged between 18 and up to 60 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Yamagata Strain FluLaval ≥ 61Y Group</title>
            <description>Subjects aged 61 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</title>
          <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 flu strains. Subjects were assessed according to 2 age categories, 18-60Y and ≥ 61Y.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="780"/>
                <count group_id="O2" value="466"/>
                <count group_id="O3" value="127"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, D0 (N=775;463;127;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="17.7" upper_limit="21.5"/>
                    <measurement group_id="O2" value="13.4" lower_limit="12.0" upper_limit="14.9"/>
                    <measurement group_id="O3" value="20.7" lower_limit="16.1" upper_limit="26.6"/>
                    <measurement group_id="O4" value="16.6" lower_limit="12.4" upper_limit="22.3"/>
                    <measurement group_id="O5" value="19.3" lower_limit="15.4" upper_limit="24.2"/>
                    <measurement group_id="O6" value="12.5" lower_limit="9.7" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, D21 (N=780;466;127;77;135;75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306.9" lower_limit="283.3" upper_limit="332.5"/>
                    <measurement group_id="O2" value="103.8" lower_limit="92.6" upper_limit="116.3"/>
                    <measurement group_id="O3" value="248.3" lower_limit="207.8" upper_limit="296.6"/>
                    <measurement group_id="O4" value="99.7" lower_limit="74.7" upper_limit="133.2"/>
                    <measurement group_id="O5" value="212.2" lower_limit="175.2" upper_limit="257.0"/>
                    <measurement group_id="O6" value="78.9" lower_limit="54.0" upper_limit="115.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D0 (N=775;463;127;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" lower_limit="14.1" upper_limit="16.8"/>
                    <measurement group_id="O2" value="17.1" lower_limit="15.4" upper_limit="19.0"/>
                    <measurement group_id="O3" value="15.4" lower_limit="12.4" upper_limit="19.1"/>
                    <measurement group_id="O4" value="11.8" lower_limit="9.1" upper_limit="15.2"/>
                    <measurement group_id="O5" value="14.8" lower_limit="12.0" upper_limit="18.3"/>
                    <measurement group_id="O6" value="15.0" lower_limit="11.7" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D21 (N=780;465;127;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.0" lower_limit="130.1" upper_limit="152.9"/>
                    <measurement group_id="O2" value="102.9" lower_limit="92.2" upper_limit="114.8"/>
                    <measurement group_id="O3" value="187.0" lower_limit="152.0" upper_limit="229.9"/>
                    <measurement group_id="O4" value="99.7" lower_limit="74.7" upper_limit="133.1"/>
                    <measurement group_id="O5" value="178.2" lower_limit="145.9" upper_limit="217.7"/>
                    <measurement group_id="O6" value="93.0" lower_limit="67.1" upper_limit="128.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D0 (N=774;466;126;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" lower_limit="19.7" upper_limit="23.7"/>
                    <measurement group_id="O2" value="42.8" lower_limit="38.4" upper_limit="47.7"/>
                    <measurement group_id="O3" value="23.9" lower_limit="19.1" upper_limit="29.9"/>
                    <measurement group_id="O4" value="41.3" lower_limit="31.6" upper_limit="53.8"/>
                    <measurement group_id="O5" value="21.6" lower_limit="17.7" upper_limit="26.5"/>
                    <measurement group_id="O6" value="38.9" lower_limit="30.3" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D21 (N=780;466;127;77;135;75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204.8" lower_limit="190.5" upper_limit="220.2"/>
                    <measurement group_id="O2" value="140.1" lower_limit="128.1" upper_limit="153.1"/>
                    <measurement group_id="O3" value="164.4" lower_limit="137.0" upper_limit="197.4"/>
                    <measurement group_id="O4" value="99.3" lower_limit="80.7" upper_limit="122.0"/>
                    <measurement group_id="O5" value="73.3" lower_limit="59.2" upper_limit="90.7"/>
                    <measurement group_id="O6" value="69.3" lower_limit="55.1" upper_limit="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D0 (N=775;466;127;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.5" lower_limit="64.3" upper_limit="77.2"/>
                    <measurement group_id="O2" value="86.7" lower_limit="78.6" upper_limit="95.6"/>
                    <measurement group_id="O3" value="66.4" lower_limit="54.0" upper_limit="81.7"/>
                    <measurement group_id="O4" value="70.8" lower_limit="57.2" upper_limit="87.7"/>
                    <measurement group_id="O5" value="64.3" lower_limit="52.5" upper_limit="81.3"/>
                    <measurement group_id="O6" value="80.0" lower_limit="63.7" upper_limit="100.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D21 (N=780;466;127;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="493.1" lower_limit="459.3" upper_limit="529.3"/>
                    <measurement group_id="O2" value="281.4" lower_limit="259.6" upper_limit="304.9"/>
                    <measurement group_id="O3" value="211.4" lower_limit="175.0" upper_limit="255.3"/>
                    <measurement group_id="O4" value="131.9" lower_limit="109.2" upper_limit="159.1"/>
                    <measurement group_id="O5" value="413.7" lower_limit="351.2" upper_limit="487.2"/>
                    <measurement group_id="O6" value="180.2" lower_limit="144.3" upper_limit="224.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</title>
        <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 flu strains.</description>
        <time_frame>At Day 0 (D0), and at Day 21 (D21) and Day 180 (D180) post vaccination.</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for persistence, which included all vaccinated subjects who had not received a vaccine forbidden in the protocol, and with available assay results at Day 180 for assessed antibodies.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</title>
          <description>Titers are presented as geometric mean titers (GMTs). The reference cut-off value was 1:10. Antibodies assessed were antibodies against the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N2), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 flu strains.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for persistence, which included all vaccinated subjects who had not received a vaccine forbidden in the protocol, and with available assay results at Day 180 for assessed antibodies.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, D0 (N=257;37;42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" lower_limit="13.9" upper_limit="19.2"/>
                    <measurement group_id="O2" value="20.4" lower_limit="12.5" upper_limit="33.2"/>
                    <measurement group_id="O3" value="13.7" lower_limit="9.3" upper_limit="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, D21 (N=257;37;42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173.5" lower_limit="146.8" upper_limit="205.0"/>
                    <measurement group_id="O2" value="211.9" lower_limit="132.4" upper_limit="339.0"/>
                    <measurement group_id="O3" value="126.0" lower_limit="77.0" upper_limit="206.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1, D180 (N=257;37;42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7" lower_limit="43.9" upper_limit="61.1"/>
                    <measurement group_id="O2" value="74.2" lower_limit="48.0" upper_limit="114.7"/>
                    <measurement group_id="O3" value="45.3" lower_limit="28.9" upper_limit="71.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D0 (N=257;37;42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" lower_limit="14.4" upper_limit="19.4"/>
                    <measurement group_id="O2" value="14.4" lower_limit="9.8" upper_limit="21.2"/>
                    <measurement group_id="O3" value="14.6" lower_limit="10.2" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D21 (N=256;37;42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.4" lower_limit="105.1" upper_limit="140.2"/>
                    <measurement group_id="O2" value="166.0" lower_limit="108.9" upper_limit="253.2"/>
                    <measurement group_id="O3" value="166.7" lower_limit="119.2" upper_limit="233.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D180 (N=257;37;42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" lower_limit="37.1" upper_limit="47.9"/>
                    <measurement group_id="O2" value="46.4" lower_limit="33.9" upper_limit="63.7"/>
                    <measurement group_id="O3" value="61.9" lower_limit="44.0" upper_limit="87.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D0 (N=257;37;42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" lower_limit="26.8" upper_limit="36.2"/>
                    <measurement group_id="O2" value="36.8" lower_limit="24.8" upper_limit="54.5"/>
                    <measurement group_id="O3" value="23.8" lower_limit="16.7" upper_limit="33.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D21 (N=257;37;42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179.0" lower_limit="158.4" upper_limit="202.2"/>
                    <measurement group_id="O2" value="137.7" lower_limit="106.0" upper_limit="179.0"/>
                    <measurement group_id="O3" value="62.9" lower_limit="43.6" upper_limit="90.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D180 (N=257;37;42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.1" lower_limit="106.8" upper_limit="134.9"/>
                    <measurement group_id="O2" value="114.2" lower_limit="92.9" upper_limit="140.4"/>
                    <measurement group_id="O3" value="68.4" lower_limit="49.4" upper_limit="94.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D0 (N=257;37;42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3" lower_limit="66.5" upper_limit="89.9"/>
                    <measurement group_id="O2" value="92.9" lower_limit="64.6" upper_limit="133.7"/>
                    <measurement group_id="O3" value="68.4" lower_limit="47.4" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D21 (N=257;37;42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399.2" lower_limit="355.8" upper_limit="447.9"/>
                    <measurement group_id="O2" value="194.8" lower_limit="153.5" upper_limit="247.2"/>
                    <measurement group_id="O3" value="275.8" lower_limit="194.1" upper_limit="392.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D180 (N=257;37;42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.1" lower_limit="226.4" upper_limit="282.9"/>
                    <measurement group_id="O2" value="167.8" lower_limit="129.2" upper_limit="217.8"/>
                    <measurement group_id="O3" value="239.6" lower_limit="171.6" upper_limit="334.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against 4 Strains of Influenza</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains.</description>
        <time_frame>At Day 21 (D21) after vaccination.</time_frame>
        <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against 4 Strains of Influenza</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains.</description>
          <population>The analysis was performed on the According-To-Protocol cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1241"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, D21 (N=1238;204;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="922"/>
                    <measurement group_id="O2" value="136"/>
                    <measurement group_id="O3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D21 (N=1237;204;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="823"/>
                    <measurement group_id="O2" value="149"/>
                    <measurement group_id="O3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D21 (N=1240;203;210))</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="685"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D21 (N=1241;204;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="680"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against 4 Strains of Influenza by Age Strata</title>
        <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-60Y and ≥ 61Y.</description>
        <time_frame>At Day 21 (D21) after vaccination.</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 18-60Y Group</title>
            <description>Subjects aged between 18 and up to 60 years inclusive at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A ≥ 61Y Group</title>
            <description>Subjects aged 61 years or above at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Victoria Strain FluLaval 18-60Y Group</title>
            <description>Subjects aged between 18 and up to 60 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval ≥ 61Y Group</title>
            <description>Subjects aged 61 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval 18-60Y Group</title>
            <description>Subjects aged between 18 and up to 60 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Yamagata Strain FluLaval ≥ 61Y Group</title>
            <description>Subjects aged 61 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against 4 Strains of Influenza by Age Strata</title>
          <description>A seroconverted subject was defined as a vaccinated subject who had either a pre-vaccination titer &lt; 1:10 and a post-vaccination titer ≥1:40, or a pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination titer. The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-60Y and ≥ 61Y.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="775"/>
                <count group_id="O2" value="466"/>
                <count group_id="O3" value="127"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1, D21 (N=775;463;127;77;135;75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="616"/>
                    <measurement group_id="O2" value="306"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="97"/>
                    <measurement group_id="O6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N1, D21 (N=775;462;127;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="544"/>
                    <measurement group_id="O2" value="279"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="104"/>
                    <measurement group_id="O6" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRI, D21 (N=774;466;126;77;135;75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="522"/>
                    <measurement group_id="O2" value="163"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="51"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FLO, D21 (N=775;466;127;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500"/>
                    <measurement group_id="O2" value="180"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="88"/>
                    <measurement group_id="O6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</title>
        <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0 (i.e. the geometric mean of the within-subject ratios of the Day 21 reciprocal HI titer to the Day 0 reciprocal HI titer). The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-60Y and ≥ 61Y.</description>
        <time_frame>At Day 21 (D21) post vaccination.</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 18-60Y Group</title>
            <description>Subjects aged between 18 and up to 60 years inclusive at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A ≥ 61Y Group</title>
            <description>Subjects aged 61 years or above at the time of vaccination received at Day 0 one dose of the GSK2282512A vaccine, from Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Victoria Strain FluLaval 18-60Y Group</title>
            <description>Subjects aged between 18 and up to 60 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval ≥ 61Y Group</title>
            <description>Subjects aged 61 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval 18-60Y Group</title>
            <description>Subjects aged between 18 and up to 60 years inclusive at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O6">
            <title>Yamagata Strain FluLaval ≥ 61Y Group</title>
            <description>Subjects aged 61 years or above at the time of vaccination received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease by Age Strata</title>
          <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0 (i.e. the geometric mean of the within-subject ratios of the Day 21 reciprocal HI titer to the Day 0 reciprocal HI titer). The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains. Subjects were assessed according to 2 age categories, 18-60Y and ≥ 61Y.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="775"/>
                <count group_id="O2" value="466"/>
                <count group_id="O3" value="127"/>
                <count group_id="O4" value="77"/>
                <count group_id="O5" value="135"/>
                <count group_id="O6" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCF – H1N1, D21 (N=775;463;127;77;135;75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="14.1" upper_limit="17.7"/>
                    <measurement group_id="O2" value="7.7" lower_limit="6.8" upper_limit="8.7"/>
                    <measurement group_id="O3" value="12.0" lower_limit="9.2" upper_limit="15.6"/>
                    <measurement group_id="O4" value="6.0" lower_limit="4.3" upper_limit="8.5"/>
                    <measurement group_id="O5" value="11.0" lower_limit="8.6" upper_limit="14.1"/>
                    <measurement group_id="O6" value="6.2" lower_limit="4.3" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCF – H3N1, D21 (N=775;462;127;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="8.3" upper_limit="10.1"/>
                    <measurement group_id="O2" value="6.0" lower_limit="5.4" upper_limit="6.8"/>
                    <measurement group_id="O3" value="12.2" lower_limit="9.3" upper_limit="15.8"/>
                    <measurement group_id="O4" value="8.5" lower_limit="6.1" upper_limit="11.8"/>
                    <measurement group_id="O5" value="12.0" lower_limit="9.2" upper_limit="15.6"/>
                    <measurement group_id="O6" value="6.2" lower_limit="4.5" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCF – BRI, D21 (N=774;466;126;77;135;75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="8.5" upper_limit="10.5"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.9" upper_limit="3.6"/>
                    <measurement group_id="O3" value="6.8" lower_limit="5.3" upper_limit="8.7"/>
                    <measurement group_id="O4" value="2.4" lower_limit="1.9" upper_limit="3.0"/>
                    <measurement group_id="O5" value="3.4" lower_limit="2.8" upper_limit="4.1"/>
                    <measurement group_id="O6" value="1.8" lower_limit="1.4" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCF – FLO, D21 (N=775;466;127;77;135;76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="6.3" upper_limit="7.7"/>
                    <measurement group_id="O2" value="3.2" lower_limit="3.0" upper_limit="3.6"/>
                    <measurement group_id="O3" value="3.2" lower_limit="2.6" upper_limit="3.8"/>
                    <measurement group_id="O4" value="1.9" lower_limit="1.5" upper_limit="2.3"/>
                    <measurement group_id="O5" value="6.3" lower_limit="5.0" upper_limit="8.0"/>
                    <measurement group_id="O6" value="2.3" lower_limit="1.8" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</title>
        <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0 (i.e. the geometric mean of the within-subject ratios of the Day 21 reciprocal HI titer to the Day 0 reciprocal HI titer). The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains.</description>
        <time_frame>At Day 21 (D21) post vaccination.</time_frame>
        <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1, 2 or 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>Victoria Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>Yamagata Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Factor for Hemagglutination Inhibition (HI) Antibodies Against 4 Strains of Influenza Disease</title>
          <description>The seroconversion factor (SCF) was defined as the fold increase in serum Hemagglutination Inhibition (HI) geometric mean titers (GMTs) post vaccination compared to Day 0 (i.e. the geometric mean of the within-subject ratios of the Day 21 reciprocal HI titer to the Day 0 reciprocal HI titer). The 4 assessed influenza strains were the FLU A/California/7/09 (H1N1), FLU A/Victoria/210/09 (H3N1), FLU B/Brisbane/60/08 (BRI) and FLU B/Florida/4/06 (FLO) flu strains.</description>
          <population>The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all vaccinated and eligible subjects for whom data concerning Immunogenicity outcomes variables were available and for whom assay results were available for antibodies against at least one study vaccine component after vaccination.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1241"/>
                <count group_id="O2" value="204"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SCF – H1N1, D21 (N=1238;204;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="11.1" upper_limit="13.2"/>
                    <measurement group_id="O2" value="9.2" lower_limit="7.5" upper_limit="11.4"/>
                    <measurement group_id="O3" value="9.0" lower_limit="7.3" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCF – H3N1, D21 (N=1237;204;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="7.2" upper_limit="8.5"/>
                    <measurement group_id="O2" value="10.6" lower_limit="8.6" upper_limit="13.0"/>
                    <measurement group_id="O3" value="9.5" lower_limit="7.7" upper_limit="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCF – BRI, D21 (N=1240;203;210)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="5.8" upper_limit="6.9"/>
                    <measurement group_id="O2" value="4.6" lower_limit="3.8" upper_limit="5.5"/>
                    <measurement group_id="O3" value="2.7" lower_limit="2.3" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SCF – FLO, D21 (N=1241;204;211)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="4.9" upper_limit="5.6"/>
                    <measurement group_id="O2" value="2.6" lower_limit="2.3" upper_limit="3.0"/>
                    <measurement group_id="O3" value="4.4" lower_limit="3.6" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
        <description>Assessed solicited local symptoms were pain, redness and swelling at the injection site. Grade 3 pain = significant pain at rest/pain that prevented normal everyday activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.</description>
        <time_frame>Within the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, on subjects for whom results were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2282512A 3 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
          <description>Assessed solicited local symptoms were pain, redness and swelling at the injection site. Grade 3 pain = significant pain at rest/pain that prevented normal everyday activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, on subjects for whom results were available.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="421"/>
                <count group_id="O3" value="422"/>
                <count group_id="O4" value="208"/>
                <count group_id="O5" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260"/>
                    <measurement group_id="O2" value="245"/>
                    <measurement group_id="O3" value="245"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (Gastr. Symptoms), headache, muscle ache, shivering, temperature – oral temperature equal to or above (≥) 38.0 degrees Celsius (°C) - and joint pain at location other than the injection site (Joint Pain). Grade 3 temperature = temperature ≥ 39.0 °C. Grade 3 symptom = symptom that prevented normal everyday activity. Related symptom = symptom assessed by the investigator as causally related to study vaccination. Joint pain data were collected for subjects in Canada and Mexico only.</description>
        <time_frame>Within the 7-day (Days 0-6) follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, on subjects for whom results were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2282512A 3 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (Gastr. Symptoms), headache, muscle ache, shivering, temperature – oral temperature equal to or above (≥) 38.0 degrees Celsius (°C) - and joint pain at location other than the injection site (Joint Pain). Grade 3 temperature = temperature ≥ 39.0 °C. Grade 3 symptom = symptom that prevented normal everyday activity. Related symptom = symptom assessed by the investigator as causally related to study vaccination. Joint pain data were collected for subjects in Canada and Mexico only.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, on subjects for whom results were available.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="417"/>
                <count group_id="O2" value="421"/>
                <count group_id="O3" value="422"/>
                <count group_id="O4" value="208"/>
                <count group_id="O5" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Fatigue (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="86"/>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="78"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="91"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Muscle Ache (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="105"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="52"/>
                    <measurement group_id="O5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Muscle Ache (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Muscle Ache (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="98"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Joint Pain (N=196;199;201;102;103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Joint Pain (N=196;199;201;102;103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Joint Pain (N=196;199;201;102;103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Gastr. (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Gastr. (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Gastr. (N=417;421;422;208;216)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal everyday activity Related: unsolicited AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>Within the 21-day (Days 0-20) follow-up period after vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2282512A 3 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal everyday activity Related: unsolicited AE assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>Subject</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="424"/>
                <count group_id="O3" value="425"/>
                <count group_id="O4" value="213"/>
                <count group_id="O5" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subject(s) with Any Unsolicited AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject(s) with Grade 3 Unsolicited AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject(s) with Related Unsolicited AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Solicited Local Symptoms After Vaccination.</title>
        <description>Solicited local symptoms were pain, redness and swelling at the injection site. Analyses of duration for solicited local symptoms were not performed.</description>
        <time_frame>Within the 7-day follow-up period after vaccination (Days 0-6)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, on subjects for whom results were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2282512A 3 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Solicited Local Symptoms After Vaccination.</title>
          <description>Solicited local symptoms were pain, redness and swelling at the injection site. Analyses of duration for solicited local symptoms were not performed.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, on subjects for whom results were available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Solicited General Symptoms After Vaccination</title>
        <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (Gastr.), headache, muscle ache, shivering, temperature (defined as oral temperature equal to or above 38.0 degrees Celsius) and joint pain at location other than the injection site (Joint Pain). Joint pain data were collected for subjects in Canada and Mexico only. Analyses of duration for solicited general symptoms were not performed.</description>
        <time_frame>Within the 7-day follow-up period after vaccination (Days 0-6)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, on subjects for whom results were available.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2282512A 3 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Solicited General Symptoms After Vaccination</title>
          <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (Gastr.), headache, muscle ache, shivering, temperature (defined as oral temperature equal to or above 38.0 degrees Celsius) and joint pain at location other than the injection site (Joint Pain). Joint pain data were collected for subjects in Canada and Mexico only. Analyses of duration for solicited general symptoms were not performed.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects, on subjects for whom results were available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Unsolicited Adverse Events (AEs) After Vaccination</title>
        <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any: any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal everyday activity. Analyses of duration for unsolicited AEs were not performed.</description>
        <time_frame>Within the 21-day (Days 0-20) follow-up period post vaccination</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2282512A 1 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O2">
            <title>GSK2282512A 2 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O3">
            <title>GSK2282512A 3 Group</title>
            <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O4">
            <title>Victoria Strain FluLaval</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
          <group group_id="O5">
            <title>Yamagata Strain FluLaval Group</title>
            <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Unsolicited Adverse Events (AEs) After Vaccination</title>
          <description>Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any: any unsolicited AE regardless of intensity or relationship to vaccination. Grade 3 = unsolicited AE that prevented normal everyday activity. Analyses of duration for unsolicited AEs were not performed.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reports of solicited local and general adverse events were collected during the 7-day (Days 0-6) follow-up period following vaccination. Reports for serious adverse events were collected throughout the study, from Day 0 to Day 180.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GSK2282512A 1 Group</title>
          <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 1. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.dominant arm.</description>
        </group>
        <group group_id="E2">
          <title>GSK2282512A 2 Group</title>
          <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 2. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E3">
          <title>GSK2282512A 3 Group</title>
          <description>Subjects received at Day 0 one dose of the GSK2282512A vaccine, Lot 3. The GSK2282512A vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E4">
          <title>Victoria Strain FluLaval Group</title>
          <description>Subjects received at Day 0 one dose of FluLaval®-VB vaccine containing the Victoria B flu strain. The FluLaval®-VB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
        <group group_id="E5">
          <title>Yamagata Strain FluLaval Group</title>
          <description>Subjects received at Day 0 one dose of FluLaval®-YB vaccine containing the Yamagata B flu strain. The FluLaval®-YB vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Gastrointestinal mucosal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="423"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="424"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="213"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="260" subjects_at_risk="417"/>
                <counts group_id="E2" subjects_affected="245" subjects_at_risk="421"/>
                <counts group_id="E3" subjects_affected="245" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="93" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="89" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="260" subjects_at_risk="417"/>
                <counts group_id="E2" subjects_affected="245" subjects_at_risk="421"/>
                <counts group_id="E3" subjects_affected="245" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="93" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="89" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="417"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="421"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Gastrointestinal adverse event(s)</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="417"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="421"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="417"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="421"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <counts group_id="E1" subjects_affected="113" subjects_at_risk="417"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="421"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="40" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Shivering</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="417"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="421"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="216"/>
              </event>
              <event>
                <sub_title>Joint pain at other location than injection site</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="417"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="421"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="422"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="208"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="216"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Analyses of duration for solicited local and general and unsolicited adverse events were not performed. Relationship to vaccination was not computed for medically-attended adverse events. Joint pain data were collected in Canada and Mexico only.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

